At two hospitals in Paris, concentrations of CAB and RPV were monitored 58 persons with HIV-RNA <50 cpm switching from oral therapy to LA-CAB/RPV. Related, a higher rate of CVF was seen in the 152-week results from ATLAS of Q2M vs QM LA-CAB/RPV. For PWH who want or need something other than daily oral therapy, LA-CAB/RPV is a good option to have available but given the higher rate of CVF with Q2M dosing, I'd pick monthly LA-CAP/RPV.

HIV controllers are rare individuals able to control infection naturally without treatment. Scientists at the Institut Pasteur are examining key characteristics of these controllers’ CD8+ T cells, with a view to replicating them in other individuals who are incapable of controlling the virus without treatment. They have successfully reprogrammed CD8+ T cells from non-controllers and bestowed them with properties of controllers’ cells.